UK healthtech company 01Health has
raised $15 million in Series A funding to support the rollout of its healthcare
platform across the UK and expand its operations in the United States. The
round was led by Gresham House Ventures, with follow-on participation from
existing investors Balderton Capital, Eka Ventures, and Wavemaker360, alongside
angel investors including Blockchain.com co-founder Nicolas Cary.

Founded in 2022 by former NHS doctor Dr Sonia Szamocki, 01Health develops technology that enables local clinics to
provide specialist healthcare services that have traditionally been
concentrated in hospitals and larger urban centres. The company was established
to address barriers to accessing specialist care, including workforce
shortages, geographic constraints, and infrastructure limitations.

To support this approach, the 01Health
platform combines specialist oversight, clinical protocols, patient
communication tools, operational workflows, and AI-powered patient acquisition
into a single system that enables specialist services to be delivered through
local clinics.

The technology has so far been used
primarily within 01Health’s own healthcare services, including the orthodontics
platform 32Co and dental sleep medicine provider Aerox Health. Through 32Co,
the company has built a nationwide network of providers offering specialist
orthodontic treatment across the UK, serving as an early application of the
platform.

While 01Health initially focused on
dentistry, the platform has been developed to support a broader range of
healthcare specialities, with trials already underway in additional clinical
areas beyond dental care.

The new funding will support the
commercial launch of the 01Health platform as a standalone offering, allowing
practices, clinic groups, and dental service organisations to license and
deploy the technology directly.

As part of this rollout, the company is
introducing the platform publicly for the first time as infrastructure that
supports the delivery of specialist care while maintaining clinical oversight
and operational consistency.

The
funding will also be used to support the company’s expansion into the United
States.